Antibodies for fluorescence-activated cell sorting (FACS) including anti-CD16/32 (Clone: 93), anti-CD3 (Clone: 17A2), anti-CD8α (Clone: 53-6.7), anti-CD11c (Clone: N418), anti-CD40 (Clone: 3/23), anti-CD44 (Clone: IM7), anti-CD62L (Clone: MEL-14), anti-CD80 (Clone: 16-10A1), anti-CD86 (Clone: GL-1), anti-Granzyme B (anti-GrzmB, Clone: GB11), anti-IFN-γ (Clone: XMG1.2), and anti-TNF-α (Clone: MP6-XT22) were purchased from BioLegend (San Diego, California, USA). iTAg Tetramer/PE-H-2 Kb OVA (SIINFEKL) was purchased from MBL (Woburn, Massachusetts, USA).
Instruments
Nuclear magnetic resonance (NMR) spectra were acquired on a Bruker AVANCE NEO 400
MHz spectrometer (Billerica, Massachusetts, USA). Electrospray ionisation mass spectra (ESI-MS) was acquired on a LTQ Orbitrap ELITE ETD (Thermo Fisher Scientific). Matrix-assisted laser desorption/ionization time-of-flight mass spectra (MALDI-TOF-MS) was aquired on an Autoflex Speed (Bruker, Billerica, Massachusetts, USA). Polycondensate neoepitope (PNE) was characterized by PL-gel permeation chromatography (GPC) 50+ Integrated GPC/SEC System (Agilent, Santa Clara, California, USA) and UltiMate TM 3000 ultra high-performance liquid chromatography (UHPLC) system (Thermo Fisher Scientific) equipped with a Hypersil Gold TM C18 selectivity LC column or a BioBasic™ SEC 300 LC column, and detectors of diode array detector (UV, DIONEX UltiMate TM 3000) and charged aerosol detector (CAD, DIONEX Corona ultra RS). The fluorescent image of sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) were taken by Bio-Rad ChemiDoc MP imaging system (Hercules, California, USA). The size of particle was measured by dynamic light scattering (DLS) on Malvern NanoZS (Worcester, UK). The transmission electron microscopy (TEM) images of PNEs were acquired on FEI Tecnai Osiris TEM instrument (FEI, Oregon, USA).
The atomic force microscopy (AFM) images of free LEQ and Pam were acquired on a Park NX-10 analytical system (Suwon, South Korea) with non-contact amplitude modulation (PPP-NCHR, Park system) in ambient condition. The fluorescence intensity of samples was measured with a Varioskan® Lux microplate reader (Thermo Fisher Scientific). All the flow cytometry data were acquired using an Attune NxT flow cytometer (Thermo Fisher Scientific).
Confocal fluorescent microscope images were acquired with a LSM 700 with 40X or 63X oil objectives (Zeiss, Oberkochen, Germany). Mouse tissue imaging was conducted with an in vivo imaging system (IVIS, PerkinElmer, Waltham, Massachusetts, USA).
Mice and cells
Experimental procedures in mouse studies were approved by the Swiss authorities (Canton of Vaud, animal protocol ID 3206) and performed in accordance with École Polytechnique Fédérale de Lausanne (EPFL) CPG guidelines. Six-to eight-week-old female Thy1.2 + C57BL/6 mice, TCR-transgenic OT-I mice (B6-Tg(TcraTcrb)1100Mjb/J) were purchased from The Jackson Laboratory (Bar Harbor, Maine, USA) or Charles River Laboratories (Lyon, France) and maintained in the animal facility. Ovalbumin (OVA)-expressing YUMM1.7 (YUMM1.7-OVA), a murine melanoma cell line, was a generous gift from Prof. Ping-Chih Ho (University of Lausanne, Lausanne, Switzerland) and cultured in DMEM complete medium supplemented by fetal bovine serum (FBS, 10%), Penicillin (100 UmL -1 ), Streptomycin (100 µgmL -1 ). Immature bone marrow-derived dendritic cells (BMDCs) were isolated from C57BL/6 mice (Charles River laboratory, Wilmington, Massachusetts, USA), and cultured in RPMI 1640 complete medium containing HI-FBS (10%), L-glutamine (2 mM), Penicillin (100 UmL -1 ), Streptomycin (100 µgmL -1 ), and 2-mercaptoethanol (β-ME, 50 µM) with GM-CSF (20 ngmL -1 ) for 6 days at 37 ºC with CO 2 (5%) before use. Naïve OT-I CD8 + T cells were isolated from splenocytes of OT-I mice with a mouse CD8 + T cell isolation kit. 
Synthesis of bi-functional Monomer B red (Mon red )
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Preparation of polycondensate neoepitopes (PNEs)
Depending on the solubility of peptides and adjuvants, synthesis of PNEs can be done in anhydrous DMSO or aqueous solution. The detailed information of composition and conditions for the syntheses of each PNE has been summarized in Table S1 . rpm. The resultant product was purified following the same procedure as described above, and characterized with DLS, GPC, HPLC, TEM, and SDS-PAGE. Gatan Orius CCD camera. ThermoMixer at 25 °C (600 rpm, 10 min). The "labeled" mixture was used for the next step without purification. Additional LEQ, Pam, or both (unlabeled) were then added the labeled mixture followed by the similar procedures for preparation and purification of PNEs as described above. For in vitro studies, 10% of LEQ or Pam was fluorescently labeled; for in vivo studies, 50% was labeled. 
PNE of SLP only [PNE(LEQ)
]
Preparation of non-degradable PNE (non-deg. PNE):

SDS-PAGE:
In vivo lymph node targeting and dendritic cell internalization
In vitro BMDC internalization
Immature BMDCs were prepared as described above. On Day 6, the BMDCs were plated in Tumor challenging: On day 37 (9 days post the final immunization), the immunized mice (as described above) were challenged subcutaneously with YUMM1.7-OVA cells (5 × 10 5 ) on the right flank. Tumor growth was monitored every other day from the fifth day post tumor inoculation. Tumor area (product of two measured orthogonal diameters) and body weight were measured every 2 days. Mice were euthanized when the body weight loss was > 15% of the animal had become moribund.
In vivo therapeutic study
Female C57BL/6 mice were subcutaneously inoculated with YUMM1.7-OVA cells ( 
Statistical analysis.
Statistical analysis was performed using GraphPad Prism 8 (GraphPad software, Inc., La Jolla, CA, USA). Unless otherwise noted, the data are presented as Mean ± SEM. Comparisons of two groups were performed by using two-tailed unpaired Student's t test. Comparisons of multiple groups at a single time point were performed by using one-way analysis of variance (ANOVA). Comparisons of survival curves were performed by using Log-rank analysis. Pvalues were presented as *P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.
Safety consideration
No unexpected or unusually high safety hazards were encountered. [1] Loading efficiency was calculated by conjugated antigen peptides in PNE / total antigen peptides added × 100% based on UHPLC characterizations.
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[2] Loading capacity was calculated by weight of conjugated antigen peptides or adjuvants in PNE / total PNE weight × 100%. Weight of conjugated peptide antigen was determined by the feeding amount and the loading efficiency; adjuvant and monomer B were assumed for quantitative loading as non-detectable free adjuvant or monomer B was found in UHPLC characterizations.
[3] Depending on the solubility of peptides and adjuvants, synthesis of PNEs can be done in DMSO or aqueous solution. The aqueous solution is phosphate-buffered saline (PBS) with adjusted pH = 8.5 with Na 2 CO 3 ). The statistical analysis between survival cruves was performed by Logrank test; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
